[{"symbol": "VRTX", "publishedDate": "2020-12-27 07:31:00", "title": "The 3 Best Healthcare Stocks to Buy for 2021", "image": "https://cdn.snapi.dev/images/v1/n/l/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6056802f2021-on-tablet-next-to-stethoscope-and-pillsjpgw700opresize.jpg", "site": "The Motley Fool", "text": "All three could be huge winners in the new year -- and over the long run.", "url": "https://www.fool.com/investing/2020/12/27/the-3-best-healthcare-stocks-to-buy-for-2021/"}, {"symbol": "VRTX", "publishedDate": "2020-12-26 05:51:00", "title": "3 Surefire Stocks to Buy With Your $600 Stimulus Check", "image": "https://cdn.snapi.dev/images/v1/1/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6061962fgovernment-stimulus-check-cash-money-us-treasury-covid-19-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Making money is easy when you're invested in high-quality businesses with clear-cut competitive advantages.", "url": "https://www.fool.com/investing/2020/12/26/3-surefire-stocks-to-buy-with-600-stimulus-check/"}, {"symbol": "VRTX", "publishedDate": "2020-12-24 18:48:15", "title": "Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/k/5/biotech33.jpg", "site": "Zacks Investment Research", "text": "Vertex Pharmaceuticals (VRTX) closed at $234.46 in the latest trading session, marking a -0.59% move from the prior day.", "url": "https://www.zacks.com/stock/news/1207637/vertex-pharmaceuticals-vrtx-stock-sinks-as-market-gains-what-you-should-know"}, {"symbol": "VRTX", "publishedDate": "2020-12-24 07:02:00", "title": "Where to Invest $5,000 Right Now", "image": "https://cdn.snapi.dev/images/v1/r/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6058402fgettyimages-1212176842jpgw700opresize.jpg", "site": "The Motley Fool", "text": "If you're worried another market crash is imminent, you'll want to scoop up these three stocks soon.", "url": "https://www.fool.com/investing/2020/12/24/where-to-invest-5000-right-now/"}, {"symbol": "VRTX", "publishedDate": "2020-12-24 06:45:00", "title": "The 3 Best Stocks for 2021", "image": "https://cdn.snapi.dev/images/v1/i/h/stocks101-12.jpg", "site": "The Motley Fool", "text": "A beaten-down biotech, a streaming star, and a coronavirus testing giant could be well-rounded additions to your portfolio.", "url": "https://www.fool.com/investing/2020/12/24/the-3-best-stocks-for-2021/"}, {"symbol": "VRTX", "publishedDate": "2020-12-23 11:18:11", "title": "Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases", "image": "https://cdn.snapi.dev/images/v1/j/e/biotech4.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) signs a licensing agreement with privately held company Skyhawk Therapeutics to discover novel small molecules that modulate RNA splicing for treating serious diseases.", "url": "https://www.zacks.com/stock/news/1200726/vertex-vrtx-inks-deal-with-skyhawk-for-serious-diseases"}, {"symbol": "VRTX", "publishedDate": "2020-12-23 06:06:00", "title": "3 Beaten-Down Growth Stocks That Can Soar in 2021", "image": "https://cdn.snapi.dev/images/v1/b/j/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6056472fbusinessman-holds-dollar-sign-grass-pot-investing-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "These high-growth companies are big-time bargains for opportunistic investors.", "url": "https://www.fool.com/investing/2020/12/23/3-beaten-down-growth-stocks-that-can-soar-in-2021/"}, {"symbol": "VRTX", "publishedDate": "2020-12-22 11:42:00", "title": "Vertex Pharmaceuticals Enters New Partnership With RNA Expert Skyhawk Therapeutics", "image": "https://cdn.snapi.dev/images/v1/5/q/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6059292fbuying-something-from-doctor-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "The large biotech firm is just the latest deep-pocketed player to ink a heavily backloaded deal with the RNA-splicing specialist.", "url": "https://www.fool.com/investing/2020/12/22/vertex-pharmaceuticals-enters-new-partnership-with/"}, {"symbol": "VRTX", "publishedDate": "2020-12-21 14:30:00", "title": "Vertex Announces FDA Approvals of TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for Use in People With CF With Certain Rare Mutations", "image": "https://cdn.snapi.dev/images/v1/z/w/press4---qaw25fhcms.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA\u00ae (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that are responsive to TRIKAFTA based on in vitro data. SYMDEKO\u00ae (tezacaftor/ivacaftor and ivacaftor) and KALYDEC", "url": "https://www.businesswire.com/news/home/20201221005675/en/Vertex-Announces-FDA-Approvals-of-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-SYMDEKO%C2%AE-tezacaftorivacaftor-and-ivacaftor-and-KALYDECO%C2%AE-ivacaftor-for-Use-in-People-With-CF-With-Certain-Rare-Mutations/"}, {"symbol": "VRTX", "publishedDate": "2020-12-21 08:43:00", "title": "3 Biotech Stocks That Could Explode Higher in 2021", "image": "https://cdn.snapi.dev/images/v1/z/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6056182fhigh-tech-laboratory-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.", "url": "https://www.fool.com/investing/2020/12/21/3-biotech-stocks-that-could-explode-higher-in-2021/"}, {"symbol": "VRTX", "publishedDate": "2020-12-21 08:15:11", "title": "5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential", "image": "https://cdn.snapi.dev/images/v1/z/j/biotech5.jpg", "site": "24/7 Wall Street", "text": "After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.", "url": "https://247wallst.com/healthcare-business/2020/12/21/5-top-biotech-stocks-to-buy-for-2021-with-massive-upside-potential/"}, {"symbol": "VRTX", "publishedDate": "2020-12-19 06:09:00", "title": "3 Top Biotech Stocks to Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/k/t/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5677182ffinancial-health-stethoscope-money-cash-hundred-bills-medical-healthcarejpgw700opresize.jpg", "site": "The Motley Fool", "text": "Each of them should enjoy strong sales growth in 2021 and beyond.", "url": "https://www.fool.com/investing/2020/12/19/3-top-biotech-stocks-to-buy-right-now/"}, {"symbol": "VRTX", "publishedDate": "2020-12-18 18:48:08", "title": "Vertex Pharmaceuticals (VRTX) Stock Moves -0.08%: What You Should Know", "image": "https://cdn.snapi.dev/images/v1/a/a/biotech37.jpg", "site": "Zacks Investment Research", "text": "Vertex Pharmaceuticals (VRTX) closed at $236.72 in the latest trading session, marking a -0.08% move from the prior day.", "url": "https://www.zacks.com/stock/news/1181887/vertex-pharmaceuticals-vrtx-stock-moves-008-what-you-should-know"}, {"symbol": "VRTX", "publishedDate": "2020-12-17 00:28:32", "title": "One Of These Red Hot Growth Stocks Is A Very Strong Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/e/f/data-internet17.jpg", "site": "Seeking Alpha", "text": "One Of These Red Hot Growth Stocks Is A Very Strong Buy Right Now", "url": "https://seekingalpha.com/article/4395112-one-of-red-hot-growth-stocks-is-strong-buy-right-now"}, {"symbol": "VRTX", "publishedDate": "2020-12-14 05:51:00", "title": "3 Surefire Stocks to Buy When the Stock Market Inevitably Crashes", "image": "https://cdn.snapi.dev/images/v1/m/d/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6045722fstock-market-crash-calling-bottom-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "Opportunistic investors should pounce on these proven winners during the next big decline.", "url": "https://www.fool.com/investing/2020/12/14/surefire-stocks-buy-stock-market-inevitably-crashe/"}, {"symbol": "VRTX", "publishedDate": "2020-12-13 06:45:00", "title": "If You Have $1,000 and 5 Years to Wait, Buy These 2 Stocks Now", "image": "https://cdn.snapi.dev/images/v1/c/r/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6043382fgettyimages-1170740969-1jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These disruptive biotech stocks could prove to be great investments in the long run.", "url": "https://www.fool.com/investing/2020/12/13/if-you-have-1000-and-5-years-to-wait-buy-these-2-s/"}, {"symbol": "VRTX", "publishedDate": "2020-12-12 15:39:24", "title": "Watch Out bluebird bio, CRISPR Is on Your Heels", "image": "https://cdn.snapi.dev/images/v1/p/o/podc14---bsu7ei4sde.jpg", "site": "The Motley Fool", "text": "The battle for beta thalassemia and sickle cell disease patients is heating up.", "url": "https://www.fool.com/investing/2020/12/12/watch-out-bluebird-bio-crispr-is-on-your-heels/"}, {"symbol": "VRTX", "publishedDate": "2020-12-12 07:20:00", "title": "3 Stocks That Are Giving Their Investors Coal in Their Stockings", "image": "https://cdn.snapi.dev/images/v1/2/m/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6044512fgettyimages-200268734-001jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.", "url": "https://www.fool.com/investing/2020/12/12/3-stocks-that-are-giving-their-investors-coal-in-t/"}, {"symbol": "VRTX", "publishedDate": "2020-12-10 10:10:07", "title": "Which Big Biotechs Short Sellers Favor Now", "image": "https://cdn.snapi.dev/images/v1/l/9/biotech40.jpg", "site": "24/7 Wall Street", "text": "The short interest data is out for November 30, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.", "url": "https://247wallst.com/healthcare-business/2020/12/10/which-big-biotechs-short-sellers-favor-now/"}, {"symbol": "VRTX", "publishedDate": "2020-12-09 06:09:00", "title": "The Best Biotech Stock on the Market Right Now", "image": "https://cdn.snapi.dev/images/v1/a/7/ver.jpg", "site": "The Motley Fool", "text": "This biotech has it all.", "url": "https://www.fool.com/investing/2020/12/09/the-best-biotech-stock-on-the-market-right-now/"}, {"symbol": "VRTX", "publishedDate": "2020-12-03 07:25:00", "title": "Is Vertex Pharmaceuticals Stock a Buy?", "image": "https://cdn.snapi.dev/images/v1/v/i/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6026192fgettyimages-909176662jpgw700opresize.jpg", "site": "The Motley Fool", "text": "This high-flying biotech is trading on the cheap.", "url": "https://www.fool.com/investing/2020/12/03/is-vertex-pharmaceuticals-stock-a-buy/"}, {"symbol": "VRTX", "publishedDate": "2020-11-30 10:22:34", "title": "Vertex: The Cheapest And Highest Quality Monopoly In The Market", "image": "https://cdn.snapi.dev/images/v1/d/m/biotech2.jpg", "site": "Seeking Alpha", "text": "Currently trading at 5-year historical PEG and PE NTM of 0.7x and 19.9x, respectively, VRTX's monopoly in cystic fibrosis is being grossly underappreciated by sell-side analysts. Long-term international expansion and pipeline opportunities represent a $4.8Bn and $9.5Bn TAM, respectively.", "url": "https://seekingalpha.com/article/4392032-vertex-cheapest-and-highest-quality-monopoly-in-market"}, {"symbol": "VRTX", "publishedDate": "2020-11-27 03:00:00", "title": "Vertex Announces European Commission Approval for SYMKEVI\u00ae (tezacaftor/ivacaftor) With KALYDECO\u00ae (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years", "image": "https://cdn.snapi.dev/images/v1/u/r/press3---rgeg9caxt5.jpg", "site": "Business Wire", "text": "LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for SYMKEVI\u00ae (tezacaftor/ivacaftor) with KALYDECO\u00ae (ivacaftor), to include the treatment of cystic fibrosis (CF) in patients ages 6 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or one copy of the F508del mutation and one copy of one of 14 mutations", "url": "https://www.businesswire.com/news/home/20201127005216/en/Vertex-Announces-European-Commission-Approval-for-SYMKEVI%C2%AE-tezacaftorivacaftor-With-KALYDECO%C2%AE-ivacaftor-for-Eligible-Children-With-Cystic-Fibrosis-Ages-6-11-Years/"}, {"symbol": "VRTX", "publishedDate": "2020-11-25 10:03:19", "title": "Big Biotech Short Sellers Seek Cover", "image": "https://cdn.snapi.dev/images/v1/x/s/biotech34.jpg", "site": "24/7 Wall Street", "text": "The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.", "url": "https://247wallst.com/healthcare-business/2020/11/25/big-biotech-short-sellers-seek-cover/"}, {"symbol": "VRTX", "publishedDate": "2020-11-21 05:51:00", "title": "5 Growth Stocks to Buy for a Biden Bull Market", "image": "https://cdn.snapi.dev/images/v1/d/v/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6013472fstock-bull-market-sp-500-dow-jones-nasdaq-invest-growth-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "The stock market could hit new highs under Biden, with these companies offering especially appetizing growth prospects.", "url": "https://www.fool.com/investing/2020/11/21/5-growth-stocks-to-buy-for-a-biden-bull-market/"}, {"symbol": "VRTX", "publishedDate": "2020-11-20 10:45:07", "title": "Odds Of Vertex's Pipeline Success Aren't Dismal As Some Fear, Bernstein Says", "image": "https://cdn.snapi.dev/images/v1/m/e/medicine-1309148-1920-282.jpg", "site": "Benzinga", "text": "Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares have come under selling pressure recently, given investor concern regarding diversity in the pipeline for this cystic fibrosis-focused biopharma. The Vertex Analyst: Bernstein analyst Analyst Vincent Chen initiated coverage of Vertex with an Outperform rating and $275 price target.", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/20/11/18466234/odds-of-vertexs-pipeline-success-arent-dismal-as-some-fear-bernstein-says"}, {"symbol": "VRTX", "publishedDate": "2020-11-19 11:43:02", "title": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies London Healthcare Conference (Transcript)", "image": "https://cdn.snapi.dev/images/v1/3/j/transcript8---banwqan5uh.jpg", "site": "Seeking Alpha", "text": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies London Healthcare Conference (Transcript)", "url": "https://seekingalpha.com/article/4390312-vertex-pharmaceuticals-incorporated-vrtx-presents-jefferies-london-healthcare-conference"}, {"symbol": "VRTX", "publishedDate": "2020-11-16 06:16:23", "title": "Here are the stocks seeing the most insider buying this week", "image": "https://cdn.snapi.dev/images/v1/m/q/here-are-the-stocks-seeing-the-most-insider-buying-this-week---igcwu1aaze.jpg", "site": "CNBC Television", "text": "CNBC's Brian Sullivan highlights the stocks seeing the most insider buying this week, on Worldwide Exchange, including names like Hanes and Vertex Pharma.", "url": "https://www.youtube.com/watch?v=dL9aXDvgS7k"}, {"symbol": "VRTX", "publishedDate": "2020-11-15 07:04:00", "title": "2 Top Pharma Stocks to Watch in November", "image": "https://cdn.snapi.dev/images/v1/y/0/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5997662fgettyimages-1050311874jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Here are two intriguing pharma stocks that may make investors rich this November.", "url": "https://www.fool.com/investing/2020/11/15/2-top-pharma-stocks-to-watch-in-november/"}, {"symbol": "VRTX", "publishedDate": "2020-11-14 13:45:17", "title": "Last Week's Notable Insider Buys: Kraft, IBM, Vertex And More", "image": "https://cdn.snapi.dev/images/v1/s/n/stoc92.jpg", "site": "Benzinga", "text": "Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason \u2014\u00a0they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was both before and after the elections.", "url": "https://www.benzinga.com/news/20/11/18372524/last-weeks-notable-insider-buys-kraft-ibm-vertex-and-more"}, {"symbol": "VRTX", "publishedDate": "2020-11-13 05:51:00", "title": "Got $250? 3 High-Growth Stocks on Sale to Buy Now", "image": "https://cdn.snapi.dev/images/v1/8/x/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6002902fsale-sign-led-discount-stock-invest-retire-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "A handful of high-flying stocks are now on sale and begging to be bought.", "url": "https://www.fool.com/investing/2020/11/13/got-250-3-high-growth-stocks-on-sale-to-buy-now/"}, {"symbol": "VRTX", "publishedDate": "2020-11-08 23:20:57", "title": "Here's Why Vertex Pharmaceuticals Fell 23.4% in October", "image": "https://cdn.snapi.dev/images/v1/7/j/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5997932fdoctor-patient-2jpgw700opresize.jpg", "site": "The Motley Fool", "text": "The biotech stopped development of a midstage drug, but the company has a backup plan.", "url": "https://www.fool.com/investing/2020/11/08/heres-why-vertex-pharmaceuticals-fell-234-in-octob/"}, {"symbol": "VRTX", "publishedDate": "2020-11-05 04:00:00", "title": "Vertex Announces European Commission Approval for KALYDECO\u00ae (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age", "image": "https://cdn.snapi.dev/images/v1/h/g/press9---lfglzwby6v.jpg", "site": "Business Wire", "text": "LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension for KALYDECO\u00ae (ivacaftor) granules to include the treatment of infants with cystic fibrosis (CF) ages 4 months and older and weighing at least 5 kg who have the R117H mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G55", "url": "https://www.businesswire.com/news/home/20201105005062/en/Vertex-Announces-European-Commission-Approval-for-KALYDECO%C2%AE-ivacaftor-as-First-and-Only-CFTR-Modulator-to-Treat-Eligible-Infants-With-Cystic-Fibrosis-as-Early-as-Four-Months-of-Age/"}, {"symbol": "VRTX", "publishedDate": "2020-11-04 14:11:00", "title": "CRISPR and Vertex Release Additional Data for Blood Disease Treatment", "image": "https://cdn.snapi.dev/images/v1/q/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5987192fdoctor-child-patinetjpgw700opresize.jpg", "site": "The Motley Fool", "text": "CTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.", "url": "https://www.fool.com/investing/2020/11/04/crispr-and-vertex-release-additional-data-for-bloo/"}, {"symbol": "VRTX", "publishedDate": "2020-11-03 07:10:00", "title": "Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?", "image": "https://cdn.snapi.dev/images/v1/7/2/vertex-neurocrine-are-these-out-of-favor-healthcare-stocks-a-buy-as-vaccine-nears.jpg", "site": "Forbes", "text": "Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme includes healthcare and pharmaceutical companies that have shown robust historical revenue growth.", "url": "https://www.forbes.com/sites/greatspeculations/2020/11/03/vertex-neurocrine-are-these-out-of-favor-healthcare-stocks-a-buy-as-vaccine-nears/"}, {"symbol": "VRTX", "publishedDate": "2020-10-30 06:05:00", "title": "Why Vertex Hit a Home Run With Its Q3 Results, but Few Are Cheering", "image": "https://cdn.snapi.dev/images/v1/h/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5974802fmale-healthcare-provider-giving-a-high-five-to-a-pediatric-patient-sitting-in-his-mothers-lapjpgw700opresize.jpg", "site": "The Motley Fool", "text": "The big biotech's recent clinical setback appears to be overshadowing its sizzling growth.", "url": "https://www.fool.com/investing/2020/10/30/why-vertex-hit-a-home-run-with-its-q3-results-but/"}, {"symbol": "VRTX", "publishedDate": "2020-10-29 23:08:07", "title": "Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q3 2020 Results - Earnings Call Transcript", "image": "https://cdn.snapi.dev/images/v1/f/k/transcript27.jpg", "site": "Seeking Alpha", "text": "Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q3 2020 Results - Earnings Call Transcript", "url": "https://seekingalpha.com/article/4382925-vertex-pharmaceuticals-inc-vrtx-ceo-reshma-kewalramani-on-q3-2020-results-earnings-call"}, {"symbol": "VRTX", "publishedDate": "2020-10-29 16:52:11", "title": "Recap: Vertex Pharmaceuticals Q3 Earnings", "image": "https://cdn.snapi.dev/images/v1/t/2/biotech20.jpg", "site": "Benzinga", "text": "Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) decreased 1.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 114.63% over the past year to $2.64, which beat the estimate of $2.32.", "url": "https://www.benzinga.com/news/earnings/20/10/18131303/recap-vertex-pharmaceuticals-q3-earnings"}, {"symbol": "VRTX", "publishedDate": "2020-10-28 08:59:39", "title": "7 Cutting-Edge Biotech Stocks for Tomorrow\u00a0", "image": "https://cdn.snapi.dev/images/v1/e/4/drugs41.jpg", "site": "InvestorPlace", "text": "Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.", "url": "https://investorplace.com/2020/10/7-cutting-edge-biotech-stocks-for-tomorrow/"}, {"symbol": "VRTX", "publishedDate": "2020-10-28 07:00:00", "title": "Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals", "image": "https://cdn.snapi.dev/images/v1/t/6/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5961592fgettyimages-1069333236jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These two rare-disease drug developers are experts at penetrating their markets.", "url": "https://www.fool.com/investing/2020/10/28/better-buy-vertex-pharmaceuticals-vs-alexion-pharm/"}, {"symbol": "VRTX", "publishedDate": "2020-10-27 10:08:00", "title": "3 Biotech Stocks I'd Buy Right Now", "image": "https://cdn.snapi.dev/images/v1/g/u/biotech23.jpg", "site": "The Motley Fool", "text": "Marketed products -- and work in the pipeline -- should translate into future growth for these shares.", "url": "https://www.fool.com/investing/2020/10/27/3-biotech-stocks-id-buy-right-now/"}, {"symbol": "VRTX", "publishedDate": "2020-10-27 09:55:02", "title": "Major Biotechs Have Short Sellers Looking Both Ways", "image": "https://cdn.snapi.dev/images/v1/p/5/biotech35.jpg", "site": "24/7 Wall Street", "text": "The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.", "url": "https://247wallst.com/healthcare-business/2020/10/27/major-biotechs-have-short-sellers-looking-both-ways/"}, {"symbol": "VRTX", "publishedDate": "2020-10-26 00:52:23", "title": "Were These Hedge Funds Right About Selling Vertex Pharmaceuticals Incorporated (VRTX)?", "image": "https://cdn.snapi.dev/images/v1/0/6/biotech5.jpg", "site": "Insider Monkey", "text": "Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) changed recently.", "url": "https://www.insidermonkey.com/blog/were-these-hedge-funds-right-about-selling-vertex-pharmaceuticals-incorporated-vrtx-887030/"}, {"symbol": "VRTX", "publishedDate": "2020-10-22 12:34:12", "title": "Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth", "image": "https://cdn.snapi.dev/images/v1/g/b/biotech9---3ac60heeb1.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "url": "https://www.zacks.com/stock/news/1081064/vertex-pharmaceuticals-vrtx-reports-next-week-wall-street-expects-earnings-growth"}, {"symbol": "VRTX", "publishedDate": "2020-10-20 11:30:15", "title": "Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?", "image": "https://cdn.snapi.dev/images/v1/t/h/biotech3.jpg", "site": "Zacks Investment Research", "text": "Is (VRTX) Outperforming Other Medical Stocks This Year?", "url": "https://www.zacks.com/stock/news/1078909/is-vertex-pharmaceuticals-vrtx-outperforming-other-medical-stocks-this-year"}, {"symbol": "VRTX", "publishedDate": "2020-10-20 09:26:00", "title": "Pick These 5 Stocks With Superb Interest Coverage Ratio", "image": "https://cdn.snapi.dev/images/v1/h/r/asset-management19-40.jpg", "site": "Zacks Investment Research", "text": "A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS Health (CVS), Amedisys (AMED) and Insperity (NSP) are sound enough to meet financial obligations.", "url": "https://www.zacks.com/stock/news/1078824/pick-these-5-stocks-with-superb-interest-coverage-ratio"}, {"symbol": "VRTX", "publishedDate": "2020-10-20 08:51:00", "title": "Bet on These 5 Top-Ranked Stocks With Strong Sales Growth", "image": "https://cdn.snapi.dev/images/v1/v/r/asset-management20.jpg", "site": "Zacks Investment Research", "text": "Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J.", "url": "https://www.zacks.com/stock/news/1078787/bet-on-these-5-top-ranked-stocks-with-strong-sales-growth"}, {"symbol": "VRTX", "publishedDate": "2020-10-20 07:39:00", "title": "Vertex Pharmaceuticals (VRTX) Enters Oversold Territory", "image": "https://cdn.snapi.dev/images/v1/g/q/biotech35.jpg", "site": "Zacks Investment Research", "text": "Vertex Pharmaceuticals (VRTX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.", "url": "https://www.zacks.com/stock/news/1078698/vertex-pharmaceuticals-vrtx-enters-oversold-territory"}, {"symbol": "VRTX", "publishedDate": "2020-10-19 16:01:00", "title": "Vertex to Announce Third-Quarter 2020 Financial Results on October 29", "image": "https://cdn.snapi.dev/images/v1/v/x/conf19.jpg", "site": "Business Wire", "text": "BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October 29, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the \"Investors\" s", "url": "https://www.businesswire.com/news/home/20201019005702/en/Vertex-to-Announce-Third-Quarter-2020-Financial-Results-on-October-29/"}, {"symbol": "VRTX", "publishedDate": "2020-10-19 12:38:00", "title": "5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates", "image": "https://cdn.snapi.dev/images/v1/n/v/drugs2.jpg", "site": "Zacks Investment Research", "text": "Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.", "url": "https://www.zacks.com/stock/news/1078363/5-big-pharma-biotech-stocks-set-to-trump-q3-earnings-estimates"}, {"symbol": "VRTX", "publishedDate": "2020-10-17 08:40:01", "title": "7 Large Biotechs Expected to Outperform This Earnings Season", "image": "https://cdn.snapi.dev/images/v1/0/0/biotech5.jpg", "site": "24/7 Wall Street", "text": "Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.", "url": "https://247wallst.com/healthcare-business/2020/10/17/7-large-biotechs-expected-to-outperform-this-earnings-season/"}, {"symbol": "VRTX", "publishedDate": "2020-10-16 11:29:31", "title": "Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20%", "image": "https://cdn.snapi.dev/images/v1/z/k/biotech36.jpg", "site": "Seeking Alpha", "text": "Excellent Entry Point For Vertex Pharmaceuticals After Giving Away -20%", "url": "https://seekingalpha.com/article/4379424-excellent-entry-point-for-vertex-pharmaceuticals-after-giving-awayminus-20"}, {"symbol": "VRTX", "publishedDate": "2020-10-16 11:16:17", "title": "Vertex (VRTX) Drops 20% After Failed Drug Trial", "image": "https://cdn.snapi.dev/images/v1/f/i/stocks141-6.jpg", "site": "Investopedia", "text": "Vertex Pharmaceuticals (VRTX) sold off on heavy volume after discontinuing trials of a promising liver disease treatment.", "url": "https://www.investopedia.com/vertex-vrtx-drops-20-after-failed-drug-trial-5082627"}, {"symbol": "VRTX", "publishedDate": "2020-10-16 07:04:00", "title": "Forget Snowflake! 2 Hyper-Growth Stocks I'd Rather Buy", "image": "https://cdn.snapi.dev/images/v1/r/a/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5737452fgettyimages-1127069581jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These two healthcare giants have a habit of beating the market, and they aren't about to stop.", "url": "https://www.fool.com/investing/2020/10/16/forget-snowflake-2-hyper-growth-stocks-id-rather-b/"}, {"symbol": "VRTX", "publishedDate": "2020-10-15 16:31:35", "title": "4 Top Stock Trades for Friday: ZM, DKNG, VRTX, GME", "image": "https://cdn.snapi.dev/images/v1/d/f/intro.jpg", "site": "InvestorPlace", "text": "Zoom Video, DraftKings, Vertex Pharma and GameStop were our top stock trades from Thursday. Here's a look at the charts.", "url": "https://investorplace.com/2020/10/4-top-stock-trades-for-friday-zm-dkng-vrtx-gme/"}, {"symbol": "VRTX", "publishedDate": "2020-10-15 15:12:00", "title": "Vertex Pulls Nasdaq Down, but Wall Street Loves Zoom", "image": "https://cdn.snapi.dev/images/v1/u/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5308742fgettyimages-1003599708jpgw700opresize.jpg", "site": "The Motley Fool", "text": "The stock market continued to lose ground on Thursday afternoon.", "url": "https://www.fool.com/investing/2020/10/15/vertex-pulls-nasdaq-down-wall-street-loves-zoom/"}, {"symbol": "VRTX", "publishedDate": "2020-10-15 12:45:14", "title": "Vertex (VRTX) is an Incredible Growth Stock: 3 Reasons Why", "image": "https://cdn.snapi.dev/images/v1/e/r/biotech11.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.", "url": "https://www.zacks.com/stock/news/1076793/vertex-vrtx-is-an-incredible-growth-stock-3-reasons-why"}, {"symbol": "VRTX", "publishedDate": "2020-10-15 11:55:28", "title": "Vertex Pharmaceuticals News: Why VRTX Stock Is Getting Slammed 20% Today", "image": "https://cdn.snapi.dev/images/v1/g/1/biotech8.jpg", "site": "InvestorPlace", "text": "Vertex Pharmaceuticals (VRTX) news for Thursday concerning bad results from one of its clinical trials is sending VRTX stock down. The post Vertex Pharmaceuticals News: Why VRTX Stock Is Getting Slammed 20% Today appeared first on InvestorPlace.", "url": "https://investorplace.com/2020/10/vertex-pharmaceuticals-news-slamming-vrtx-stock/"}, {"symbol": "VRTX", "publishedDate": "2020-10-15 10:11:00", "title": "Vertex to End Phase II Study on AAT Deficiency Candidate", "image": "https://cdn.snapi.dev/images/v1/a/j/biotech6---ttrwnmty64.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.", "url": "https://www.zacks.com/stock/news/1076503/vertex-to-end-phase-ii-study-on-aat-deficiency-candidate"}, {"symbol": "VRTX", "publishedDate": "2020-10-15 09:51:41", "title": "Why Vertex Pharmaceuticals Stock Is Slumping Today", "image": "https://cdn.snapi.dev/images/v1/t/p/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5898462fgettyimages-1183908006jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Investors are concerned about Vertex's pipeline after a rare miss in the clinic.", "url": "https://www.fool.com/investing/2020/10/15/why-vertex-pharmaceuticals-stock-is-slumping-today/"}, {"symbol": "VRTX", "publishedDate": "2020-10-15 07:31:50", "title": "Analysts say Vertex's stock is under pressure after drug development failure", "image": "https://cdn.snapi.dev/images/v1/1/0/106298733-1576513139338gettyimages-880891422---fkgvojnfrz.jpeg", "site": "Market Watch", "text": "Shares of Vertex Pharmaceuticals Inc. were down 9.8% in premarket trading on Thursday, the day after the drug maker said it had stopped development of an experimental therapy aimed at treating Alpha-1 antitrypsinase deficiency, which can cause lung and liver disease. Vertex cited the therapy's safety and pharmacokinetic profile of VX-814 as observed in a Phase 2 clinical trial.", "url": "https://www.marketwatch.com/story/analysts-say-vertexs-stock-is-under-pressure-after-drug-development-failure-2020-10-15"}, {"symbol": "VRTX", "publishedDate": "2020-10-14 19:07:59", "title": "Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment", "image": "https://cdn.snapi.dev/images/v1/v/e/vert2---wlkyzqam7o.jpg", "site": "Investors Business Daily", "text": "Shares of Vertex plunged after hours Wednesday after the company announced it planned to stop testing on a drug designed to treat protein deficiencies. VRTX stock fell by double digits.", "url": "https://www.investors.com/news/technology/vtx-stock-tumbles-stops-testing-protein-deficiency-treatment/"}, {"symbol": "VRTX", "publishedDate": "2020-10-14 17:07:00", "title": "Vertex stock falls after protein-deficiency drug development stopped", "image": "https://cdn.snapi.dev/images/v1/a/s/asde13.jpg", "site": "Market Watch", "text": "Vertex Pharmaceuticals Inc. VRTX stock fell in the extended session Wednesday after the biotech company said it would stop developing a drug to treat an inherited protein deficiency that can cause lung and liver disease. Vertex shares fell 9% after hours, following a 1.7% decline to close the regular session at $271.46.", "url": "https://www.marketwatch.com/story/vertex-stock-falls-after-protein-deficiency-drug-development-stopped-11602709656"}, {"symbol": "VRTX", "publishedDate": "2020-10-14 12:10:14", "title": "Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?", "image": "https://cdn.snapi.dev/images/v1/e/z/biotech34.jpg", "site": "Zacks Investment Research", "text": "Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "url": "https://www.zacks.com/stock/news/1075788/will-vertex-vrtx-beat-estimates-again-in-its-next-earnings-report"}, {"symbol": "VRTX", "publishedDate": "2020-10-14 06:06:00", "title": "4 Growth Stocks You Can Safely Hold Through 2030", "image": "https://cdn.snapi.dev/images/v1/7/5/esy27.jpg", "site": "The Motley Fool", "text": "These high-growth companies offer competitive advantages that'll favor buy-and-hold investors.", "url": "https://www.fool.com/investing/2020/10/14/4-growth-stocks-you-can-safely-hold-through-2030/"}, {"symbol": "VRTX", "publishedDate": "2020-10-12 12:01:42", "title": "Vertex Looks To Target 10% Of Cystic Fibrosis Population Not Yet Achieved By Its Current CFTR Modulators", "image": "https://cdn.snapi.dev/images/v1/z/o/biotech18.jpg", "site": "Seeking Alpha", "text": "Vertex Pharmaceuticals strikes a deal with Moderna for a second time to develop a gene-edited therapy for cystic fibrosis; first partnership entails the use of mRNA and the second is LNP.", "url": "https://seekingalpha.com/article/4378618-vertex-looks-to-target-10-of-cystic-fibrosis-population-not-yet-achieved-current-cftr"}, {"symbol": "VRTX", "publishedDate": "2020-10-12 10:03:08", "title": "Short Sellers Need to Find a Clue on Major Biotechs", "image": "https://cdn.snapi.dev/images/v1/1/u/biotech9.jpg", "site": "24/7 Wall Street", "text": "The short interest data are out for September 30, the most recent settlement date.", "url": "https://247wallst.com/healthcare-business/2020/10/12/short-sellers-need-to-find-a-clue-on-major-biotechs/"}, {"symbol": "VRTX", "publishedDate": "2020-10-12 09:45:00", "title": "Booming Gene Editing Market to Pep Up These 5 Biotech Stocks", "image": "https://cdn.snapi.dev/images/v1/v/e/biotech12.jpg", "site": "Zacks Investment Research", "text": "Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.", "url": "https://www.zacks.com/stock/news/1074350/booming-gene-editing-market-to-pep-up-these-5-biotech-stocks"}, {"symbol": "VRTX", "publishedDate": "2020-10-09 06:10:00", "title": "Investing $1,000 in These 3 Stocks Would Be a Really Smart Move Right Now", "image": "https://cdn.snapi.dev/images/v1/0/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5939852fwoman-holding-book-with-light-bulb-and-moneyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "These stocks are in great shape to deliver strong growth over the long run.", "url": "https://www.fool.com/investing/2020/10/09/investing-1000-in-these-3-stocks-would-be-a-really/"}, {"symbol": "VRTX", "publishedDate": "2020-10-07 05:51:00", "title": "Got $1,000? 3 Stocks to Buy if the Market Crashes", "image": "https://cdn.snapi.dev/images/v1/z/u/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5939932fstock-market-crash-plunge-dollar-newspaper-invest-dow-sp-500-gettyjpgw700opresize.jpg", "site": "The Motley Fool", "text": "A plunging stock market would be the perfect opportunity to put your money to work in these great companies.", "url": "https://www.fool.com/investing/2020/10/07/got-1000-3-stocks-to-buy-if-the-market-crashes/"}, {"symbol": "VRTX", "publishedDate": "2020-10-06 09:01:00", "title": "Add These 5 Stocks With Impressive Interest Coverage Ratio", "image": "https://cdn.snapi.dev/images/v1/u/k/fod922-1.jpg", "site": "Zacks Investment Research", "text": "Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.", "url": "https://www.zacks.com/stock/news/1071442/add-these-5-stocks-with-impressive-interest-coverage-ratio"}, {"symbol": "VRTX", "publishedDate": "2020-10-04 07:32:00", "title": "3 Top Stocks to Buy in October", "image": "https://cdn.snapi.dev/images/v1/k/k/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5631972fgettyimages-1132660268gogfbjpgw700opresize-2.jpg", "site": "The Motley Fool", "text": "Three very different stocks with at least one thing in common -- huge growth prospects.", "url": "https://www.fool.com/investing/2020/10/04/3-top-stocks-to-buy-in-october/"}, {"symbol": "VRTX", "publishedDate": "2020-10-04 07:15:00", "title": "What You Need to Know About Orphan Drug Designations", "image": "https://cdn.snapi.dev/images/v1/u/y/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5932382fgettyimages-1242453956jpgw700opresize.jpg", "site": "The Motley Fool", "text": "Their addressable markets may be small, but that doesn't mean developers will fail to profit from these boundary-breaking drugs.", "url": "https://www.fool.com/investing/2020/10/04/what-you-need-to-know-about-orphan-drug-designatio/"}, {"symbol": "VRTX", "publishedDate": "2020-10-04 06:20:00", "title": "2 Top Biotech Stocks to Buy in October", "image": "https://cdn.snapi.dev/images/v1/t/s/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5938112fgettyimages-1087219198jpgw700opresize.jpg", "site": "The Motley Fool", "text": "These companies show that specialization can be an excellent competitive strategy.", "url": "https://www.fool.com/investing/2020/10/04/2-top-biotech-stocks-to-buy-in-october/"}, {"symbol": "VRTX", "publishedDate": "2020-10-03 07:38:00", "title": "Where Will Vertex Pharmaceuticals Be in 5 Years?", "image": "https://cdn.snapi.dev/images/v1/f/d/biotech40.jpg", "site": "The Motley Fool", "text": "The biotech company is up more than 23% in 2020, but where will it be in five years?", "url": "https://www.fool.com/investing/2020/10/03/where-will-vertex-pharmaceuticals-be-in-5-years/"}]